Insilico Medicine, an end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development company, has announced that it has closed a $255 million Series C financing led by Warburg Pincus. The financing was also participated by current investors including Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD…
